Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOAC versus no anticoagulation for stroke prevention in transient stress-related atrial fibrillation
NL-OMON59488Phase 4Recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabigatran in Atrial fibrillation (AFib) (2 arms), sponsored by Hamilton Health Sciences. Primary endpoints: Co-primary outcome 1 and Co-primary outcome 2. Started Jan 2024; status: recruiting.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON59488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59488.